# SOLVAY

### Roadshow presentation

post Q2 2024 earnings



#### Philippe Kehren CEO



Alexandre Blum cfo



Profile & Strategy



## A New Chapter

## We are mastering the elements essential to our world



#### Our Ambition

Consolidate **#1 market position** 

Be THE benchmark on cost

Sustain top quartile profitability and returns

Deliver carbon neutrality through process innovation



## At a glance





## Leadership across businesses

## Essential to multiple end-markets



1 Special Chem and Peroxides net sales take into account the transfer of eH202 business from Special Chem to Peroxides (effective in 2024)

2 Special Chem net sales exclude thermal insulation business (phased out in 2023) 3 Peroxides : including changes related to Peroxidos do Brazil and Zhenjiang

Based on 2023 net sales



## Balanced global geographical exposure





## Strategy founded on 4 strategic priorities





## **Structural cost savings**

Rapid ramp up in first years



€**300**m by 2028 **50**% in first 2 years

### 25% SG&A

Fit for purpose organization New ERP

### 35% Plant Fixed Costs

Operational excellence Footprint optimization

**40%** Operational efficiency

Logistics & procurement Process innovation

## 2023 ESG performance demonstrates strong progress on climate and better life

Drastically reducing our CO<sub>2</sub> emissions with 27 major energy transition projects

|  | 2023 | 2021 | Progress | Targets                                   |
|--|------|------|----------|---|
| Scope 1 & 2 GHG Emissions (Mt)             | 7.3  | 9.0  | -19%     | -30% by 2030                              |
| Scope 3 GHG Emissions (Mt)                 | 12.4 | 14.7 | -16%     | -20% by 2030                              |
| Coal Phase out (Petajoules)                | 24.4 | 27.2 | -10%     | Coal phase out by 2030                    |
| Safety (RIIR)                              | 0.27 | 0.34 | -21%     | Aim for zero                              |
| Diversity (% of women mid/sen. management) | 26.3 | 28   | -1.7pts  | Gender parity by 2035                     |
| UN Living wage initiative                  | NEW  |      | Pilot    | Living wage for 100% of workforce by 2026 |

## Clear prioritization of Cash usage

#### ~€4bn Levered pre-CAPEX cash flow Indicative over 2024-28

| Priority 1<br>Essential CAPEX     | <ul> <li>→ One Planet</li> <li>→ Sustenance</li> </ul>  | ~1/3           |      |
|-----------------------------------|---|----------------|------|
| _                                 |   |                |      |
| Priority 2<br>Dividends           | 'Stable to increasing' policy   | ~1/3           |      |
|                                   |   | 1 1 35 2 16 30 |      |
| Priority 3<br>More value creation | <ul> <li>→ Selective investment projects</li> <li>→ Deleveraging</li> <li>→ Further shareholder return</li> </ul> | ~1/3           |      |
| 10                                |   | so             | LVAY |

## Value unlocked by the separation



- → Standardization
- → End-to-End optimization
- → Lowest cost operations
- $\rightarrow$  Process innovation for sustainable operations
- Attractive shareholder returns
- $\rightarrow$  Investments for efficiency and decarbonization

0

→ Maintain IG rating





Financials



## Full year 2023 results

Another year of leadership and resilience



### Q2 2024 results

Continued sequential improvement of EBITDA and Margin driving solid FCF



## Q2 EBITDA bridge



€272m in Q2 2024 vs €357m in Q2 2023

## Slight volume growth & positive product mix

#### Lower net pricing

from soda ash, as expected very resilient in other businesses

#### Lower fixed costs

structural savings initiatives and overall strong cost control

## Structural cost savings in H1'24



#### Solid FCF generation : €246m YTD Supported by resilient EBITDA, prudent Capex and Working capital



vs €120m in Q2 2024 €126m in Q1 2024

> Resilient EBITDA Performance

+3% sequentially

**Prudent Capex** 

Disciplined WC management SOLVAY

## Capital structure Adequate debt level



#### S&P RATING: BBB-Stable outlook

#### Net debt: €1.6 Bn

Net pension liabilities: €0.7 Bn Environmental liabilities: €0.5 Bn

Leverage ratio: 1.5x



### Outlook

Expectations for 2024

Underlying EBITDA organic growth ranging between **-10% to -15%** compared to 2023 restated (previously -10% to -20%)

Free Cash Flow<sup>1</sup> higher than €300 million

(previously higher than €260 million)

## 2028 Targets

| Underlying EBITDA Growth (in %)  | Mid Single-Digit per year average |  |  |  |
|----------------------------------|-----------------------------------|--|--|--|
| Underlying EBITDA Margin (in %)  | Mid to High 20s                   |  |  |  |
| Total Gross Savings              | €300 mn run-rate                  |  |  |  |
| Free cash flow Conversion (in %) | Exceed mid 30s                    |  |  |  |
| ROCE (in %)                      | Increasing to low 20s             |  |  |  |
| Stable to increasing dividends   |                                   |  |  |  |
| Investn                          | nent grade credit rating          |  |  |  |



Baseline 2023, organic basis





#### Chief Executive Officer

## **Global Leadership Team**



## Soda ash: market leadership with strong cash generation





## Soda ash: global market leader in both Soda Ash and Bicar

### Global #1 position in Soda Ash

Soda Ash global capacity (excl. China) in kt (2022)

#### Global #1 position in **Bicar** Bicar global capacity (incl. China) in kt (2023)

 Other (36\*)
 NAM (35\*)
 Natural (43\*)

 10\*
 EUROPE (57\*)
 Synthetic (57\*)

 13\*
 Solvay
 Production method

 Market Capacity
 Solvay
 Production method

 Solvay
 Top 5 global competitors
 Others



SOLVA

Incoming capacity additions in the U.S.

## Peroxides: Market leadership and strong cash-generation



## Peroxides: undisputed market leader



## Silica: Strong financial performance





## Silica: The global HDS market leader



o ⊑≺ ¶∏ Leader at key tire brands

#### HDS global market size

~ €1.4bn

→ Strong position at Tier 1 brands through global reach & security of supply

→ Balanced presence in Original Equipment & <u>Replacement Markets</u>

Sources : Company, Note



## Coatis: Strong cash conversion



## Coatis: Major regional producer of essential chemicals in Latam with two integrated businesses Solvents (~50%)



Asia • Brazil • Europe • Latin America • North America

## Special Chem: demonstrated EBITDA resilience and solid cash generation





## Fluorine: Strong regional presence enabling safe & high quality service to our customers



Leader in selected applications



- → Metal Treatment
- → Refinery
- → Quartz (Electronics)

Nocolok

→ Automotive
→ HVAC

## Rare Earth: strong positions enabled by global industrial footprint and tailored products



### o ☐ ↓ Leader in Key Markets

#### Automotive Catalysis



- → The go-to partner of Tier 1 automotive washcoat players
- → Very strong presence at China players
- Deep IP portfolio



- Advanced cerium based high performance materials
- Leading solution for the latest generations of semiconductors



## A long track record of resilient growth, margin expansion and cash generation



34 Source: Solvay pro forma unaudited figures for 2020-2023 and Solvay audited financials (pre-2020)

GDP Growth in key market segments with pockets going beyond

**Cost Savings** from G&A and Operational

G&A and Operational Excellence

#### SOLVAY

## Profitable growth drivers



## Best-in-class ROCE to improve further



Return on Capital Employed (%)



Top Line Growth Cost Reduction Value Creation investments Asset Efficiency Gains

#### SOLVAY

36 Source: Solvay Internal data; Solvay audited financials (2019)

## 2023 Restated Underlying EBITDA and Net Sales

| in € million                        | impact | Underlying EBITDA | Underlying Net Sales |
|-------------------------------------|--------|-------------------|----------------------|
| 2023 as published                   |        | 1,246             | 4,880                |
| phase-out thermal insulation        | scope  | -54               | -107                 |
| phase-out third party energy supply | scope  | -41               | N/A                  |
| Dis-synergies                       | scope  | -12               | N/A                  |
| Zhenjiang                           | scope  | -8                | -25                  |
| Peroxidos do Brasil                 | APM    | +23               | +163                 |
| 2023 Restated                       |        | 1,154             | 4,911                |

In addition, on January 1st 2024, as communicated in Solvay's Capital Market Day presentation on November 13th 2023, the "eH2O2" (electronic-grade hydrogen peroxide) business has been transferred from GBU Special Chem part of Performance Chemicals to GBU Peroxides part of Basic Chemicals.

The 2023 quarterly underlying sales and EBITDA restated figures will be published in April, ahead of the Q1 2024 publication.





- Capital expenditure (capex): Cash paid for the acquisition of tangible and intangible assets presented in cash flows from investing activities, and cash paid on the lease liabilities (excluding interests paid), presented in cash flows from financing activities, excluding acquisition of assets associated with the partial demerger project. This indicator is used to manage capital employed in the Group.
- Cash conversion: (Underlying EBITDA Capex from continuing operations) / Underlying EBITDA.
- Free cash flow: Cash flows from operating activities (excluding cash flows linked to acquisitions or disposals of subsidiaries, cash outflows of Voluntary Pension Contributions, as they are deleveraging in nature as a reimbursement of debt and cash flows related to internal management of portfolio such as one-off external costs of internal carveout and related taxes...), cash flows from investing activities (excluding cash flows associated with the partial demerger project), and other investments, and excluding loans to associates and non-consolidated investments, and recognition of factored receivables), payment of lease liabilities, and increase/decrease of borrowings related to environmental remediation. Prior to the adoption of IFRS 16, operating lease payments were included within free cash flow. Following the application of IFRS 16, because leases are generally considered to be operating in nature, free cash flow incorporates the payment of the lease liability (excluding the interest expense). Excluding this item in the free cash flow would result in a significant improvement of prior periods, whereas the operations themselves have not been affected by the implementation of IFRS 16. It is a measure of cash generation, working capital efficiency and capital discipline of the Group.
- Free cash flow to Solvay shareholders: Free cash flow after payment of net interests, coupons of perpetual hybrid bonds and dividends to non-controlling interests. This represents the cash flow available to Solvay shareholders, to pay their dividend and/or to reduce the net financial debt.
- Free cash flow conversion: Calculated as the ratio between the free cash flow to Solvay shareholders (before netting of dividends paid to noncontrolling interest) and underlying EBITDA.
- Levered pre-CAPEX cash flow: Free cash flow to Solvay shareholders before Capital expenditure (capex).
- Vet financial debt: Non-current financial debt + current financial debt cash & cash equivalents other financial instruments (current and non-current). Underlying net debt reclassifies as debt 100% of the hybrid perpetual bonds, considered as equity under IFRS. It is a key measure of the strength of the Group's financial position and is widely used by credit rating agencies.
- V Net sales: Sales of goods and value added services corresponding to Solvay's know-how and core business. Net sales exclude Revenue from non- core activities.
- Organic growth: Growth of Net sales or underlying EBITDA excluding scope changes (related to small M&A not leading to restatements) and forex conversion effects. The calculation is made by rebasing the prior period at the business scope and forex conversion rate of the current period. Scope impact includes the phasing out of Solvay's thermal insulation activities which were previously part of Special Chem as well as the phasing out of Solvay's third party energy supply activities that were previously included in Corporate Costs. Organic growth is the net of dissynergies related to PO2.
- RIIR: Reportable Injury & Illness rate. number of reportable injury or illness per 200,000 work hours.
- ROCE: Return on Capital Employed, calculated as the ratio between underlying EBIT (before adjustment for the amortization of PPA) and capital employed. Capital employed consists of net working capital, tangible and intangible assets, goodwill, rights-of-use assets, investments in associates & joint ventures and other investments, and is taken as the average of the situation at the end of the last 4 quarters.
- Underlying: Underlying results are deemed to provide a more comparable indication of Solvay's fundamental performance over the reference periods. They provide readers with additional information on the Group's underlying performance over time as well as the financial position and they are consistent with how the business' performance and financial position are reported to the Board of Directors and the Executive Committee.

#### CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, the statements about the Partial Demerger, as well as other statements that are predictions of or indicate plans, strategies, goals, future events or intentions. In particular, these statements relate to (and include data relating to) Solvay management's business strategies, capital expenditures and other investments, growth of existing operations and expansion plans, its financial situation and its cash flow, as well as forecasts, other future events, trends or objectives and expectations concerning, in particular, the markets in which it operates, its strategy its growth and its results. These statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The statements in the presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions. The statements are not historical facts and should not be construed as a guarantee that the stated facts and/or data will occur. Although Solvay believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. As such, undue reliance should not be placed on such statements. Should one or more of these risks and uncertainties materialize, or should any underlying assumptions prove incorrect, or any other factor impact those statements, the Solvay Group's or Syensgo's actual results, plans, objectives and expectations, as well as the timing and consummation of the Partial Demerger and related transactions, may differ materially from those expressed or implied in the forward-looking statements. The inclusion of such statements should not be regarded as a representation that such results, plans, trends or objectives will be achieved. Important factors that could cause actual results, plans, trends and objectives to differ materially from those expressed in such statements include, among others, Solvay's and Svensgo's ability to satisfy the necessary conditions to consummate the Partial Demerger, or that the Partial Demerger will be completed, within the expected time frame, on the expected terms or at all; Solvay's ability to realize the anticipated benefits of the Partial Demerger, in full or at all; the expected tax treatment of the Partial Demerger; potential uncertainty during the pendency of the Partial Demerger that could affect Solvay's financial performance; the possibility of disruption, including changes to existing business relationships, disputes, litigation or unanticipated costs in connection with the Partial Demerger and related transactions; uncertainty of Solvay's or Svensgo's financial performance and ability to succeed as standalone publicly traded companies following completion of the Partial Demerger; negative effects of the announcement or pendency of the Partial Demerger and related transactions on the value and future market price of Solvay's or Svensoo's securities as standalone publicly traded companies and/or on their financial performance: general economic factors, such as interest rate, currency exchange rate fluctuations and changing market conditions; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development; the impact of business combinations, divestitures and restructurings, including any reorganizations to be carried out in connection with the contemplated transaction; adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and import/export and trade laws; the impact of products withdrawals; regulatory approval processes; the ability to implement its R&I projects and efforts: the ability to capture any opportunities and market share growth from its principal end-markets or the identified growth platforms, to the extent realized; the ability to identify and invest in value-creating projects and apply its value-based pricing model; the ability to deliver on its strategic initiatives; and the ability to improve efficiency in the use of its existing assets. Solvay undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.

#### FINANCIAL INFORMATION INCLUDED IN THIS PRESENTATION

This presentation contains certain financial information relating to Solvay before completion of the Partial Demerger, as well as separate indicative financial information with respect to Solvay in its expected configuration immediately following the completion of the Partial Demerger (also known as "EssentialCo"), though Solvay's name will not change. The financial information relating to Solvay has been derived from Solvay's audited consolidated financial statements for the periods indicated or from other published financial or management data. The indicative financial information for the years 2020, 2021 and 2022 and for the six-month period ended June 30, 2023 has been derived from the unaudited pro forma combined financial statements of EssentialCo for the years 2020, 2021 and 2022 and for the six-month is qualified by the detailed information contained therein, including in the notes thereto. The unaudited pro forma combined financial statements of EssentialCo for the years 2020, 2021 and 2022 are available on Solvay's website (www.solvay.com). Information derived from such pro forma combined financial statements of EssentialCo for the years 2020, 2021 and 2022 are available on Solvay's website (www.solvay.com). Information derived from such pro forma combined financial statements of EssentialCo for the years 2020, 2021 and 2023 are available on Solvay's website (www.solvay.com). Information derived from such pro forma combined financial statements of EssentialCo for the years 2020, 2023 are available on Solvay's website (www.solvay.com). Information derived from such pro forma combined financial statements is presented on the business units of Solvay that will form part of EssentialCo is presented herein for purposes of illustrating indicative trends. However, the financial information for these business units was prepared on a basis that is different from the basis of preparation of the unaudited pro forma combined financial statements of EssentialCo. Accordingly, the trend information for the elevent f

information. In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures, used by Solvay in analyzing its operating trends, financial performance and financial position and providing investors with additional information considered useful and relevant regarding its results. These non-GAAP financial measures are not recognized measures under IFRS or any other generally accepted accounting standards, and they generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, Solvay's audited financial statements and related notes prepared in accordance with IFRS. For a definition of each non-GAAP financial measure included in this presentation and a reconciliation from such non-GAAP financial measure to the relevant line item, subtotal or total in EssentialCo's financial statements, please refer to Section 7.3, "Alternative Performance Measures" of the information Document.

This presentation contains statistics, data and other information about Solvay's markets, market sizes, market shares and other industry data pertaining to Solvay's business and markets. The market information presented in this presentation has been obtained from various sources. Such information is provided solely for information purposes. Although Solvay believes the market information included herein to be reliable as of the date of this presentation, Solvay has not independently verified such information for accuracy or completeness. Additionally, competitors may define the markets in which they operate or key performance indicators in a manner different from that of Solvay.

Certain calculated figures (including data expressed in thousands or millions) and percentages presented in the presentation have been rounded. Where applicable, the totals presented in this presentation may slightly differ from the totals that would have been obtained by adding the exact amounts (not rounded) for these calculated figures.